Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy

Ji Yeong An, Hyoung Il Kim, Jae Ho Cheong, WooJin Hyung, Choong Bae Kim, Sung Hoon Noh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. Materials and Methods: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated. Results: Eleven patients (14.8%) demonstrated ypT0 and the remaining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery. Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial.

Original languageEnglish
Pages (from-to)888-894
Number of pages7
JournalYonsei Medical Journal
Volume54
Issue number4
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Chemoradiotherapy
Stomach Neoplasms
Neoadjuvant Therapy
Drug Therapy
Survival
Gastrectomy
Tumor Biomarkers
Disease-Free Survival
Recurrence
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

An, Ji Yeong ; Kim, Hyoung Il ; Cheong, Jae Ho ; Hyung, WooJin ; Kim, Choong Bae ; Noh, Sung Hoon. / Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. In: Yonsei Medical Journal. 2013 ; Vol. 54, No. 4. pp. 888-894.
@article{ee4e49b6559a44808afc759d11f7c021,
title = "Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy",
abstract = "Purpose: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. Materials and Methods: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated. Results: Eleven patients (14.8{\%}) demonstrated ypT0 and the remaining 63 patients (85.2{\%}) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4{\%}, 70{\%}, and 52.2{\%}. The 1-, 3-, 5-year overall survivals were 88.5{\%}, 67.5{\%}, and 51.2{\%}, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6{\%} of them demonstrated recurrence of the tumor within 6 months after curative surgery. Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial.",
author = "An, {Ji Yeong} and Kim, {Hyoung Il} and Cheong, {Jae Ho} and WooJin Hyung and Kim, {Choong Bae} and Noh, {Sung Hoon}",
year = "2013",
month = "7",
day = "1",
doi = "10.3349/ymj.2013.54.4.888",
language = "English",
volume = "54",
pages = "888--894",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. / An, Ji Yeong; Kim, Hyoung Il; Cheong, Jae Ho; Hyung, WooJin; Kim, Choong Bae; Noh, Sung Hoon.

In: Yonsei Medical Journal, Vol. 54, No. 4, 01.07.2013, p. 888-894.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy

AU - An, Ji Yeong

AU - Kim, Hyoung Il

AU - Cheong, Jae Ho

AU - Hyung, WooJin

AU - Kim, Choong Bae

AU - Noh, Sung Hoon

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Purpose: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. Materials and Methods: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated. Results: Eleven patients (14.8%) demonstrated ypT0 and the remaining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery. Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial.

AB - Purpose: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. Materials and Methods: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated. Results: Eleven patients (14.8%) demonstrated ypT0 and the remaining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery. Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial.

UR - http://www.scopus.com/inward/record.url?scp=84878253550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878253550&partnerID=8YFLogxK

U2 - 10.3349/ymj.2013.54.4.888

DO - 10.3349/ymj.2013.54.4.888

M3 - Article

VL - 54

SP - 888

EP - 894

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -